Squarepoint Ops LLC raised its stake in shares of Stemline Therapeutics Inc (NASDAQ:STML) by 114.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,620 shares of the biopharmaceutical company’s stock after buying an additional 14,182 shares during the quarter. Squarepoint Ops LLC owned about 0.08% of Stemline Therapeutics worth $253,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of STML. Empire Life Investments Inc. lifted its stake in Stemline Therapeutics by 277.2% in the 4th quarter. Empire Life Investments Inc. now owns 373,863 shares of the biopharmaceutical company’s stock valued at $3,552,000 after acquiring an additional 274,742 shares in the last quarter. Polar Capital LLP lifted its stake in Stemline Therapeutics by 12.1% in the 4th quarter. Polar Capital LLP now owns 2,302,666 shares of the biopharmaceutical company’s stock valued at $21,875,000 after acquiring an additional 248,616 shares in the last quarter. BlackRock Inc. lifted its stake in Stemline Therapeutics by 6.3% in the 3rd quarter. BlackRock Inc. now owns 1,969,492 shares of the biopharmaceutical company’s stock valued at $32,694,000 after acquiring an additional 116,672 shares in the last quarter. Fosun International Ltd bought a new stake in Stemline Therapeutics in the 4th quarter valued at approximately $572,000. Finally, Knott David M lifted its stake in Stemline Therapeutics by 48.0% in the 4th quarter. Knott David M now owns 155,795 shares of the biopharmaceutical company’s stock valued at $1,480,000 after acquiring an additional 50,508 shares in the last quarter. Institutional investors and hedge funds own 47.32% of the company’s stock.
STML opened at $14.00 on Wednesday. Stemline Therapeutics Inc has a 1-year low of $7.82 and a 1-year high of $20.55. The firm has a market capitalization of $609.98 million, a P/E ratio of -4.68 and a beta of 1.14.
STML has been the topic of a number of analyst reports. Piper Jaffray Companies set a $23.00 price objective on Stemline Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 18th. HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of Stemline Therapeutics in a research note on Friday, January 25th. ValuEngine upgraded Stemline Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, March 21st. Roth Capital set a $33.00 price objective on Stemline Therapeutics and gave the stock a “buy” rating in a research note on Sunday, December 23rd. Finally, BidaskClub upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, December 27th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $26.00.
COPYRIGHT VIOLATION WARNING: “Squarepoint Ops LLC Has $253,000 Stake in Stemline Therapeutics Inc (STML)” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2019/04/17/squarepoint-ops-llc-has-253000-stake-in-stemline-therapeutics-inc-stml.html.
Stemline Therapeutics Profile
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
Want to see what other hedge funds are holding STML? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stemline Therapeutics Inc (NASDAQ:STML).
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.